Neurmedix
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6165 Greenwich Dr Ste 150, San Diego, Ca...Website
www.neurmedixinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neurmedix
NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders, and certain oncological diseases. The companys leading clinical candidate, 17?-ethynyl-androst-5-ene-3b,7b,17b-triol, compound code NE3107 is a small molecule, orally administered, anti-inflammatory, insulin-sensitizing agent with a novel mechanism of action is entering a pivotal phase 3 clinical trial for the treatment of mild to moderate Alzheimers disease. Clinical trials in Parkinsons disease, multiple myeloma and prostate cancer are also planned to begin in 2021. Nearly $100 million has been invested on developing NE3107. The companys focus is on diseases with tremendous unmet medical needs in order to expedite FDA approvals and commercialization, minimize capital requirement and optimize shareholder value.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurmedix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Neurmedix recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Neurmedix is spiking on competitors!
Funding: Get notified immidiatlly once Neurmedix has new funding data
Click to see if Neurmedix had a recent Job posting/layoffs
Product Launch: Get notified when Neurmedix launches new products
Check if Neurmedix has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Neurmedix, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Neurmedix
Recommended Actions
Find VP level buyers at Neurmedix
Find 2 more new buyers
Compare Similar Companies to Neurmedix
Compare insights from companies similar to Neurmedix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neurmedix
<$5M
1-10
Private
-
2003
N/A
Company Profile Activity
Activity Insights
Neurmedix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurmedix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurmedix.
Neurmedix Tech Stack
A closer look at the technologies used by Neurmedix
Neurmedix News & Media
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced amendments to certain terms for the previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., (NeurMedix), a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegener
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurmedix
Sign Up For FreeTo access detailed company insights
NeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders, and certain oncological diseases. The companys leading clinical candidate, 17?-ethynyl-androst-5-ene-3b,7b,17b-triol, compound code NE3107 is a small molecule, orally administered, ant... Read More
